Characterization of Propylene Glycol–Mitigated Freeze/Thaw Agglomeration of a Frozen Liquid nOMV Vaccine Formulation by Static Light Scattering and Micro-Flow Imaging

References

1. 1.↵
   1. Zapata M. I.,
   2. Feldkamp J. R.,
   3. Peck G. E.,
   4. White J. L.,
   5. Hem S. L.

   Mechanism of freeze-thaw instability of aluminum hydroxycarbonate and magnesium hydroxide gels. J. Pharm. Sci. 1984, 73 (1), 3–8.

   OpenUrlPubMed
2. 2.↵
   1. Jones Braun L.,
   2. Tyagi A.,
   3. Perkins S.,
   4. Carpenter J.,
   5. Sylvester D.,
   6. Guy M.,
   7. Kristensen D.,
   8. Chen D.

   Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants. Vaccine 2008, 27 (1), 72–79.

   OpenUrlPubMed
3. 3.↵
   WHO. Temperature Sensitivity of Vaccines. WHO: Geneva, 2006. WHO/IVB/06.10.
4. 4.↵
   1. Dipika M,
   2. Matthias J. R.,
   3. Garrison M. M.,
   4. Newland S.,
   5. Nelson C.

   Freezing temperatures in the vaccine cold chain: a systematic literature review. Vaccine 2007, 25 (20), 3980–3986.

   OpenUrlPubMed
5. 5.↵
   1. Salnikova M. S.,
   2. Davis H. B.,
   3. Mensch C. D.,
   4. Celano L.,
   5. Thiriot D.

   Influence of formulation pH and suspension state on freezing-induced agglomeration of aluminum adjuvants. J. Pharm. Sci. 2011, 101 (3), 1050–1062.

   OpenUrlPubMed
6. 6.↵
   FDA/CDER. Inactive Ingredient Search for Approved Drug Products Database. Website. Available at http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm. Accessed December 3, 2013.
7. 7.↵
   1. Clausi A. L.,
   2. Merkley S. A.,
   3. Carpenter J. F.,
   4. Randolph T. W.

   Inhibition of aggregation of aluminum hydroxide adjuvant during freezing and drying. J. Pharm. Sci. 2008, 97 (6), 2049–2061.

   OpenUrlPubMed
8. 8.↵
   1. Clausi A.,
   2. Cummiskey J.,
   3. Merkley S.,
   4. Carpenter J. F.,
   5. Jones Braun L.,
   6. Randolph T. W.

   Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine. J. Pharm. Sci. 2008, 97 (12), 5252–5262.

   OpenUrlPubMed
9. 9.↵
   1. Shirodkar S.,
   2. Hutchinson R. L.,
   3. Perry D. L.,
   4. White J. L.,
   5. Hem S. L.

   Aluminum compounds used as adjuvants in vaccines. Pharm. Res. 1990, 7 (12), 1282–1288.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.
    1. Clausi A. L.,
    2. Morin A.,
    3. Carpenter J. F.,
    4. Randolph T. W.

    Influence of protein conformation and adjuvant aggregation on the effectiveness of aluminum hydroxide adjuvant in a model alkaline phosphatase vaccine. J Pharm Sci. 2009, 98 (1), 114–121.

    OpenUrlPubMed
11. 11.↵
    1. Singh M.

    1. Hem S. L.,
    2. Harm H. E.

    Chapter 4. Aluminum-Containing Adjuvants: Properties, Formulation, and Use. In Vaccine Adjuvants and Delivery Systems; Singh M., Ed.; Wiley Interscience: Hoboken, NJ, 2007; pp 81–114.
12. 12.↵
    1. Exley C.,
    2. Siesjo P.,
    3. Eriksson H.

    The immunobiology of aluminum adjuvants: How do they really work? Trends Immunol. 2009, 31 (3), 103–109.

    OpenUrl
13. 13.↵
    1. Gupta R. K.

    Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 1997, 32 (3), 155–172.

    OpenUrl
14. 14.↵
    Malvern Instruments. Laser Diffraction for Particle Size Analysis: Why Use Mie Theory? Lab Plus International 2000, 28.